niacinamide has been researched along with Fibromatosis, Aggressive in 4 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Fibromatosis, Aggressive: A childhood counterpart of abdominal or extra-abdominal desmoid tumors, characterized by firm subcutaneous nodules that grow rapidly in any part of the body but do not metastasize. The adult form of abdominal fibromatosis is FIBROMATOSIS, ABDOMINAL. (Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A recent randomized trial demonstrated that sorafenib improved progression free survival (PFS) in patients with desmoid tumors despite many patients experiencing stable disease or spontaneous regression without treatment." | 9.69 | A cost analysis of sorafenib for desmoid tumors. ( Ford, CN; Johns, MS; Lee, WM; Merritt, WT; Petrelli, NJ; Rhodes, L; Sheldon, Y; Thompson, M; Tiesi, GJ, 2023) |
| "Sorafenib is currently one of the recommended treatments for symptomatic patients with desmoid-type fibromatosis (DTF)." | 8.31 | Efficacy and tolerability of sorafenib in desmoid-type fibromatosis: A need to review dose. ( Barwad, A; Dhamija, E; Gamangatti, S; Gangadharaiah, BB; Garg, V; Rastogi, S; Upadhyay, A, 2023) |
| "After Institutional Review Board (IRB) approval, we reviewed data for 26 patients with desmoid tumors treated with sorafenib." | 7.77 | Activity of Sorafenib against desmoid tumor/deep fibromatosis. ( Ahn, L; Antonescu, CR; D'Adamo, DR; Gounder, MM; Hameed, M; Keohan, ML; Lefkowitz, RA; Maki, RG; Singer, S; Stout, K, 2011) |
| "A recent randomized trial demonstrated that sorafenib improved progression free survival (PFS) in patients with desmoid tumors despite many patients experiencing stable disease or spontaneous regression without treatment." | 5.69 | A cost analysis of sorafenib for desmoid tumors. ( Ford, CN; Johns, MS; Lee, WM; Merritt, WT; Petrelli, NJ; Rhodes, L; Sheldon, Y; Thompson, M; Tiesi, GJ, 2023) |
| "Sorafenib is currently one of the recommended treatments for symptomatic patients with desmoid-type fibromatosis (DTF)." | 4.31 | Efficacy and tolerability of sorafenib in desmoid-type fibromatosis: A need to review dose. ( Barwad, A; Dhamija, E; Gamangatti, S; Gangadharaiah, BB; Garg, V; Rastogi, S; Upadhyay, A, 2023) |
| "After Institutional Review Board (IRB) approval, we reviewed data for 26 patients with desmoid tumors treated with sorafenib." | 3.77 | Activity of Sorafenib against desmoid tumor/deep fibromatosis. ( Ahn, L; Antonescu, CR; D'Adamo, DR; Gounder, MM; Hameed, M; Keohan, ML; Lefkowitz, RA; Maki, RG; Singer, S; Stout, K, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Johns, MS | 1 |
| Merritt, WT | 1 |
| Rhodes, L | 1 |
| Ford, CN | 1 |
| Thompson, M | 1 |
| Lee, WM | 1 |
| Sheldon, Y | 1 |
| Petrelli, NJ | 1 |
| Tiesi, GJ | 1 |
| Garg, V | 1 |
| Gangadharaiah, BB | 1 |
| Rastogi, S | 1 |
| Upadhyay, A | 1 |
| Barwad, A | 1 |
| Dhamija, E | 1 |
| Gamangatti, S | 1 |
| Benech, N | 1 |
| Walter, T | 1 |
| Saurin, JC | 1 |
| Gounder, MM | 1 |
| Lefkowitz, RA | 1 |
| Keohan, ML | 1 |
| D'Adamo, DR | 1 |
| Hameed, M | 1 |
| Antonescu, CR | 1 |
| Singer, S | 1 |
| Stout, K | 1 |
| Ahn, L | 1 |
| Maki, RG | 1 |
1 trial available for niacinamide and Fibromatosis, Aggressive
| Article | Year |
|---|---|
A cost analysis of sorafenib for desmoid tumors.
Topics: Aged; Costs and Cost Analysis; Fibromatosis, Aggressive; Humans; Medicare; Niacinamide; Phenylurea C | 2023 |
3 other studies available for niacinamide and Fibromatosis, Aggressive
| Article | Year |
|---|---|
Efficacy and tolerability of sorafenib in desmoid-type fibromatosis: A need to review dose.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Drug-Related Side Effec | 2023 |
Desmoid Tumors and Celecoxib with Sorafenib.
Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Female | 2017 |
Activity of Sorafenib against desmoid tumor/deep fibromatosis.
Topics: Adolescent; Adult; Benzenesulfonates; Female; Fibromatosis, Aggressive; Humans; Magnetic Resonance I | 2011 |